• Building next generation RNA

Half-year Report 2023

Circio announced its first half year 2023 results on Thursday 24 August 2023.

Webcast: 10:00 a.m. CET the same day

Class-Leading Clinical Data

  • ONCOS-102 has shown 35 %

    response rate in PD-1 resistant melanoma, which is one of the best published data sets in this immunotherapy-resistant cancer type

CEO Statement

During 2022 we reinvented Targovax at the same time as delivering on all major milestones for our three technology platforms. We have thus established a solid foundation to unlock the full potential of our portfolio, and rapidly progress our circular RNA platform to solve important unmet medical needs and deliver value for our shareholders.

Circio aims to activate the patient’s immune system to fight cancer, and thereby bring benefit to cancer patients with few available treatment alternatives